What Acupath’s ArteraAI Prostate Test rollout reveals about the next phase of precision oncology
Acupath adds ArteraAI Prostate Test to its pathology workflow. Find out what it means for AI prostate cancer risk stratification today.
Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?
AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.
Artera’s EU breakthrough in AI cancer testing opens a bigger battle over workflow, trust, and scale
Artera has won CE marking for its AI prostate and breast cancer assays. Read what this means for oncology diagnostics, adoption, and global expansion.